Notable Labs

Notable Labs EBIT Margin

The EBIT Margin (Operating Margin) of Notable Labs (NTBLQ) as of Nov 10, 2026 is -4,728.06 %. In the previous year, EBIT Margin (Operating Margin) was -4,977.27 % — a change of -5.01% (higher).

EBIT Margin

-4,728.06 %

YoY

-5.01%

Last updated:

EBIT Margin (Operating Margin) of Notable Labs is 2023 -4,728.06 % . EBIT Margin (Operating Margin) of Notable Labs was 2022 -4,977.27 % . It decreases by -5.01% higher compared to the previous year.

For Notable Labs, the operating (EBIT) margin of -4,728.1% is down versus -3,585.7% a few years ago.

The Notable Labs EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-76.91 USD
Jan 1, 2018
-3,601.69 USD
Jan 1, 2019
-3,585.71 USD
Jan 1, 2020
-2,660.87 USD
Jan 1, 2021
-3,896.10 USD
Jan 1, 2022
-4,977.27 USD
Jan 1, 2023
-4,728.06 USD
The Notable Labs EBIT Margin history
YEAREBIT MarginYoY
-4,728.06 %-5.01%
-4,977.27 %+27.75%
-3,896.10 %+46.42%
-2,660.87 %-25.79%
-3,585.71 %-0.44%
-3,601.69 %+4,582.88%
-76.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

EBIT Margin (Operating Margin) of Notable Labs is -4,728.06 % in 2023.

EBIT Margin (Operating Margin) of Notable Labs changed from -4,977.27 % to -4,728.06 %, representing a -5.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Notable Labs

All Key Metrics — Notable Labs